SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa

by Ysios Capital

SparingVision today announces a key advancement in its Phase I/II clinical trial for SPVN06, the Company’s lead gene-agnostic investigational gene therapy for the treatment of retinitis pigmentosa (...

Read more

SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa

by Ysios Capital

PRODYGY is a Phase I/II study to assess the safety, tolerability, efficacy and quality of life following a single subretinal injection of SPVN06 in the worst-seeing eye of adult patients with RP due t...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un ensayo de microscopía dinámica del ...

by CSIC - Centro Superior de Investigaciones Científicas

La revista ‘Nature Protocols’ selecciona esta técnica como “pro...

Photos Stream